NCT04770467View on ClinicalTrials.gov

A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
COVID-19
Interventions
DRUG

BRII-196 and BRII-198

BRII-196 and BRII-198 given by intravenous administration

DRUG

Placebo

Placebo given by intravenous administration

Trial Locations (1)

Unknown

Investigative Site 1, Hong Kong

Sponsors
All Listed Sponsors
lead

Brii Biosciences, Inc.

INDUSTRY

NCT04770467 - A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 | Biotech Hunter | Biotech Hunter